CONMED (CNMD)
(Delayed Data from NYSE)
$73.22 USD
-0.74 (-1.00%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $73.21 -0.01 (-0.01%) 5:18 PM ET
4-Sell of 5 4
B Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.22 USD
-0.74 (-1.00%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $73.21 -0.01 (-0.01%) 5:18 PM ET
4-Sell of 5 4
B Value B Growth F Momentum B VGM
Zacks News
Why Is Conmed (CNMD) Up 13.2% Since Last Earnings Report?
by Zacks Equity Research
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Do Options Traders Know Something About CONMED (CNMD) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to CONMED (CNMD) stock based on the movements in the options market lately.
New Strong Sell Stocks for August 19th
by Zacks Equity Research
ARRY, BSM and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on August 19, 2024.
New Strong Sell Stocks for August 15th
by Zacks Equity Research
ARCO, CNMD and CVS have been added to the Zacks Rank #5 (Strong Sell) List on August 15, 2024.
New Strong Sell Stocks for August 5th
by Zacks Equity Research
AMX, CNH and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on August 5, 2024.
CONMED (CNMD) Q2 Earnings Beat, Sales Rise Y/Y, '24 View Cut
by Zacks Equity Research
CONMED (CNMD) beats second-quarter earnings estimates on the back of higher revenues and lower costs and expenses. However, the result reflects the continued impact of supply chain issues.
Here's What Key Metrics Tell Us About Conmed (CNMD) Q2 Earnings
by Zacks Equity Research
Although the revenue and EPS for Conmed (CNMD) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Conmed (CNMD) Q2 Earnings Beat Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 6.52% and 0.74%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Conmed (CNMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Staar Surgical (STAA) Soars 7.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Staar Surgical (STAA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Henry Schein (HSIC) Down 4.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merit Medical (MMSI) Up 5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CONMED (CNMD) Q1 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
CONMED's (CNMD) adjusted first-quarter earnings and revenues beat estimates on the back of strong U.S. and International markets as well as supply-chain improvement.
Conmed (CNMD) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Conmed (CNMD) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Conmed (CNMD) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 6.76% and 1.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Smith+Nephew (SNN) Expands in Australia With New Alliance
by Zacks Equity Research
The latest partnership allows Smith+Nephew (SNN) to complement its existing implant range with the cutting-edge navigation technology of NAVBIT.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
CONMED (CNMD) Misses on Q4 Earnings, Beats Revenue Estimates
by Zacks Equity Research
CONMED's (CNMD) adjusted fourth-quarter earnings misses while sales beat estimates on the back of strong growth in the United States and international markets. Gross margin improves with a rise in sales.
Here's What Key Metrics Tell Us About Conmed (CNMD) Q4 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Conmed (CNMD) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Conmed (CNMD) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of -4.51% and 1.77%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Earnings on Feb 1: RVTY, CAH & More
by Debanjana Dey
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how CAH, RVTY, CNMD, SRDX and BDX are placed ahead of their earnings releases.
Ahead of Conmed (CNMD) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Conmed (CNMD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.